HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aceto’s Biotron Labs Acquisition Latest Thrust In Wave Of VMS Sector Investment During Pandemic

Executive Summary

Not only are larger firms acquiring smaller competitors or expanding portfolios by adding brands, private equity and venture capital groups accelerate buying into sector. The latest is New Mountain Capital-owned Aceto acquiring Biotron Laboratories and its Talus Mineral business.

You may also be interested in...



Nestle Harvests Plant-Based Protein Firm Orgain As Latest US Nutrition Business Investment

Nestle Health Science has expanded its nutritional footprint steadily since 2017 but investing in Orgain, with option to fully acquire in 2024 brings its first business working exclusively with plant-based ingredients.

New Chapter For Nutrition21: Private Equity Owner

RoundTable Healthcare Partners establishes Everwell Health Holdings for investing in consumer health and wellness functional ingredient businesses; Nutrition21 is Everwell’s first investment.

Plantible $21.5M Funding Round Reflects Investor Confidence In Plant-Based Protein Market

Business developed as vertically integrated agricultural platform to produce Rubi Protein from Lemna, commonly known as duckweed. Rubi allows supplement and food firms to match the taste and texture of animal-based products with more sustainable plant-based ingredients.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel